(Q40708166)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8094320%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

review article

1 reference

title

Second-line chemotherapy for recurrent carcinoma of the ovary (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8094320%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

1 reference

J T Thigpen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8094320%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

R B Vance

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8094320%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

T Khansur

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8094320%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

language of work or name

English

0 references

publication date

1 February 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8094320%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8094320%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

volume

71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8094320%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

issue

4 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8094320%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

page(s)

1559-1564

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8094320%20AND%20SRC:MED&resulttype=core&format=json

A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study

24 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

High-dose carboplatin in refractory ovarian cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Second-line treatment of advanced measurable ovarian cancer with iproplatin: A Southwest oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Hexamethylmelamine as a single second-line agent in ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

High-dose cisplatin in hypertonic saline in refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.2820710422

7 January 2021

Identifiers

DOI

10.1002/CNCR.2820710422

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8094320%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

1 reference